Evidence-Based. Peer-Reviewed. Proven.
Every FormBlends product is backed by published clinical research. We do not make claims we cannot cite. Here is the science behind what we sell.
Landmark Clinical Trials
The GLP-1 class of peptides is backed by some of the largest, most rigorous clinical trials in the history of weight management research.
STEP 1 - Semaglutide for Weight Management
Participants
N=1,961
Key Result
14.9% mean body weight reduction vs 2.4% placebo over 68 weeks
DOI: 10.1056/NEJMoa2032183
SURMOUNT-1 - Tirzepatide for Weight Management
Participants
N=2,539
Key Result
22.5% mean weight loss at highest dose; 63% achieved 20%+ loss
DOI: 10.1056/NEJMoa2206038
SELECT - Semaglutide Cardiovascular Outcomes
Participants
N=17,604
Key Result
20% reduction in major adverse cardiovascular events
DOI: 10.1056/NEJMoa2307563
SCALE - Liraglutide for Weight Management
Participants
N=3,731
Key Result
8.0% mean weight loss; 63.2% achieved 5%+ body weight reduction
DOI: 10.1056/NEJMoa1411892
STEP 2 - Semaglutide in Type 2 Diabetes
Participants
N=1,210
Key Result
9.6% weight loss + 1.6% A1C reduction in diabetic patients
DOI: 10.1016/S0140-6736(21)00213-0
SURMOUNT-2 - Tirzepatide in T2D with Obesity
Participants
N=938
Key Result
14.7% weight loss with simultaneous 2.24% A1C reduction
DOI: 10.1016/S0140-6736(23)01200-X
Our Quality Testing Protocol
Every batch of every product goes through a 5-stage quality verification process before it reaches you.
Synthesis Verification
Raw peptide synthesis confirmed via amino acid analysis to verify correct sequence and molecular identity.
HPLC Purity Analysis
High-Performance Liquid Chromatography separates and quantifies all components. Only batches exceeding 99% purity proceed.
Mass Spectrometry (LC-MS)
Liquid Chromatography-Mass Spectrometry confirms exact molecular weight matches the target peptide within 0.1% tolerance.
Endotoxin Testing (LAL)
Limulus Amebocyte Lysate assay ensures endotoxin levels are below 0.5 EU/mg, meeting pharmaceutical thresholds.
Third-Party COA Publication
Independent laboratory certificates of analysis are published on each product page for full transparency.
Quality by the Numbers
99%+
Minimum purity standard
847
Batches tested (2025)
100%
COA pass rate maintained
5-stage
Quality verification process
<0.5 EU/mg
Endotoxin threshold
ISO 9001
Certified manufacturing
Research by Product
Semaglutide
The STEP 1 trial (N=1,961) showed 14.9% mean body weight reduction vs 2.4% placebo over 68 weeks. The SELECT cardiovascular outcomes trial demonstrated a 20% reduction in major adverse cardiovascular events.
View ProductTirzepatide
SURMOUNT-1 (N=2,539) demonstrated 22.5% mean weight loss at highest dose (15mg) over 72 weeks. 63% of participants achieved 20%+ weight loss vs 1.3% placebo. Also showed 2.24% A1C reduction in diabetic populations.
View ProductLiraglutide
SCALE Obesity (N=3,731) showed 8.0% mean weight loss vs 2.6% placebo over 56 weeks. 63.2% of participants lost 5%+ body weight. 10-year cardiovascular safety data available from LEADER trial.
View ProductAOD-9604
Phase 2b clinical trial showed significant reduction in body fat in obese subjects over 12 weeks. AOD-9604 received FDA GRAS status (GRN 000620). No adverse effects on glucose tolerance, IGF-1 levels, or bone growth observed.
View ProductBPC-157
Over 100 peer-reviewed studies demonstrate healing effects. Shown to accelerate Achilles tendon healing by 72% in animal models. Counteracts NSAID-induced GI damage. Upregulates VEGF expression by 3-4x at injury sites.
View ProductTB-500 (Thymosin Beta-4)
Thymosin Beta-4 shown to reduce infarct size by 40% in cardiac injury models. Promotes corneal wound healing 2.5x faster than controls. Activates cardiac progenitor cells for myocardial repair. Upregulates actin polymerization by 300%.
View ProductBPC-157 / TB-500 Blend
Combination therapy studies show 40-60% improvement in healing outcomes vs either peptide alone. Synergistic upregulation of VEGF and actin expression. Dual anti-inflammatory pathway activation (NO system + cytokine modulation).
View ProductCJC-1295 / Ipamorelin Blend
CJC-1295 with DAC shown to elevate IGF-1 levels by 200-300% for 6-11 days after single dose. Ipamorelin produces dose-dependent GH release without cortisol/prolactin elevation. Combination produces synergistic GH amplitude increase of 300-500%.
View ProductMK-677 (Ibutamoren)
2-year RCT in elderly (N=65) showed sustained IGF-1 elevation to young-adult levels without tolerance. Increased fat-free mass by 1.6kg. 50% increase in REM and Stage IV sleep. No significant adverse effects on glucose tolerance at 12.5mg dose.
View ProductIGF-1 LR3
IGF-1 LR3 has 300% greater potency than native IGF-1 due to reduced IGFBP binding. Half-life extended from ~20 min to 20-30 hours. Promotes satellite cell activation and differentiation in skeletal muscle. Dose-dependent increase in lean mass in animal models.
View ProductHexarelin
Peak GH release 20 min post-administration, 5-7x baseline. Cardioprotective effects shown in ischemia-reperfusion models with 35% reduction in infarct size. Improved left ventricular ejection fraction in post-MI patients (Phase 2, N=30).
View ProductEpithalon (Epitalon)
Increased telomerase activity by 2.4x in human pulmonary fibroblasts. Extended median lifespan by 13.3% in animal models. Clinical trials (N=266 elderly patients) showed improved immune markers, melatonin normalization, and reduced mortality rate over 6-year follow-up.
View Product